Tag: Cancer: Leukemia
Measurable Residual Disease Negativity Tied to Survival in AML
AML patients without MRD have higher estimated rates of five-year disease-free, overall survival
Late Morbidity, Mortality Down for Survivors of Childhood ALL
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy
Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy
ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
Antileukemic therapy recommended over supportive care for patients who are candidates for such therapy
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease
Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
Greater intake of foods rich in antioxidants tied to lower rates of infection, mucositis during treatment
Infection Risk Up in Month After CAR T-Cell Immunotherapy
Infection rates increase in patients with ALL aged ≤26 years in first month, then decrease at days 29 to 90
Dexrazoxane Preserves Cardiac Function in Pediatric Leukemia
Beneficial for patients with AML receiving anthracyclines, with no impact on event-free, overall survival
Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML
Prognostic Score Predicts Time to First Treatment in Leukemia
Prognostic score for early-stage CLL based on genetic test, lymphocyte count, lymph node status
